Thursday, 23rd June Advances in Neuroblastoma Research Congress 2016
ANZCHOG Welcome
9:00AM - 9:10AM
Thursday, 23rd June
Hall A
Plenary Session 4
9:10AM - 10:30AM
Thursday, 23rd June
Hall A
Chairs: Gudrun Schleiermacher & Sue Cohn
Sponsored by:
- A Phase 3 randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children’s Oncology Group (COG) study - Julie R Park
- Phase II randomized trial of irinotecan/temozolomide (I/T) with temsirolimus (TEM) or dinutuximab plus granulocyte colony stimulating factor (DIN/GMCSF) in children with refractory or relapsed neuroblastoma: a report from the Children’s Oncology Group (COG) - Rajen Mody
- Second malignancies in patients with neuroblastoma: a report from the international neuroblastoma risk group project - Mark A Applebaum
- The way towards an international mIBG skeletal score for high risk neuroblastoma: the statistical perspective - Ulrike Pötschger
- Final results of the randomised short term infusion (STI) of ch14.18/CHOmAB immunotherapy in combination with Aldesleukin: a report on outcome and toxicities from the HR-NBL1/SIOPEN trial - Ruth Ladenstein
Morning Tea
10:30AM - 11:00AM
Thursday, 23rd June
Exhibition Area
Parallel 11 Biomarkers and Novel Approaches
11:00AM - 12:30PM
Thursday, 23rd June
Meeting room 1 & 2
Chairs: Per Kogner & Pat Reynolds
- Catecholamine metabolites: novel diagnostic insight, correlations with biological features and prediction of clinical outcome in patients with neuroblastoma - Iedan Verly
- High frequency of Cytosine to Adenine mutations in neuroblastoma correlates with genomic aberrations in 8-Oxo-Guanine repair pathway - Anne Hakkert
- The FOXM1 target gene BIRC5 (survivin) is a top ranked dosage sensitive gene located on the common large copy number 17q gained segment in neuroblastoma. - Geertrui Denecker
- Identification of novel small molecule compounds to restore sensitivity to trophic factor withdrawal in MYCN-initiated death resistant cells - Belamy B Cheung
- Metronomic Topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence - Sabine Taschner-Mandl
- High MYCN, low MYC, low CERS4, and low anti-apoptotic BCL2 gene family expression are associated with sensitivity to fenretinide in neuroblastoma cell lines and PDXs - Michael M Song
Parallel 12 Immunotherapy and Early Phase Trials
11:00AM - 12:30PM
Thursday, 23rd June
Meeting room 3 & 4
Chairs: Daniel Morgenstern & Rajen Mody
- Preclinical assessment of CD171-directed CAR T cell adoptive therapy for childhood neuroblastoma: CE7 epitope target safety and product manufacturing feasibility - Annette Kuenkele
- Phase II clinical trial with long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 (IL2) showed clinical efficacy and improved toxicity in patients with high risk neuroblastoma. - Holger N Lode
- Humanized anti-gd2 antibody (hu14.18k322a) with Chemotherapy +/- parental natural killer (nk) cells in children with recurrent/ refractory Neuroblastoma - Sara M. Federico
- Tumor-associated macrophage polarization state and the dynamic nature of PDL1 expression in neuroblastomas - Shahab Asgharzadeh
- Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01: A phase 1 study of autologous T-cells lentivirally transduced to express CD171-specific Chimeric Antigen Receptors (CAR) for recurrent/refractory high-risk neuroblastoma (HR-NB) - Julie R Park
- Phase II study of alisertib, irinotecan, and temozolomide in children with relapsed and refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy (NANT) consortium - Steven G. DuBois
Neuroblastoma Update - 1
11:00AM - 12:30PM
Thursday, 23rd June
Hall A
Chairs: Sue Cohn & Andy Pearson
- Overview of neuroblastoma epidemiology and genetic predisposition - Sharon Diskin
- Actionable genomic mutations - Frank Speleman
- Updates on the International Neuroblastoma Risk Group (INRG). Classification System and Interactive INRG Database (iINRGdb) - Susan Cohn
- Overview of treatment for low- and intermediate-risk patients - Gudrun Schleiermacher
Lunch
12:30PM - 1:30PM
Thursday, 23rd June
Exhibition Area
Follow-Up ANRA Advisory Board Meeting
12:30PM - 1:30PM
Thursday, 23rd June
Meeting Room 8
Industry sponsored workshop: United Therapeutics
12:45PM - 1:25PM
Thursday, 23rd June
Meeting room 1 & 2
Sponsored by:
Parallel 13 - Genome Wide Analysis and Genetic Variation
1:30PM - 3:30PM
Thursday, 23rd June
Meeting room 3 & 4
Chairs: Frank Westermann & Katleen De Preter
- Whole exome and deep targeted sequencing of clinically aggressive neuroblastomas reveal recurrent somatic mutations in pathways involved in cancer progression - Mario Capasso
- Identification of germline mutations in 776 children with neuroblastoma - Sharon J. Diskin
- Fusion-transcripts are associated with an unfavorable phenotype in neuroblastoma - Fakhera Ikram
- Clonal reconstruction in neuroblastoma shows enrichment of mutations in cell survival and DNA-repair pathways at relapse - Paul Deveau
- Chromosomal rearrangements juxtapose active enhancer elements to oncogenes in high‐risk neuroblastoma - Frank Westermann
- Molecular risk assessment of neuroblastoma patients eliminates the necessity of clinical prognostic markers - Carolina Rosswog
- Genetic variants in BARD1 and KIF15 are associated with MYCN-amplification in neuroblastoma - Mark A Applebaum
- Pharmacogenetics of treatment response in patients with high-risk neuroblastoma, a Children’s Oncology Group study - Navin Pinto
Parallel 14 Clinical Awards Session
1:30PM - 3:30PM
Thursday, 23rd June
Meeting room 1 & 2
Chairs: Holger Lode & Jed Nuchtern
- Predicting “early” relapse/progression/death in children with INRGSS Stage M neuroblastoma using clinical and biologic factors: An INRG database analysis - Lucas Moreno
- Revised Children’s Oncology Group (COG) risk stratification incorporating the international neuroblastoma risk group staging system - Meredith S Irwin
- High-dose 131I-MIBG treatment incorporated into tandem HDCT/auto-SCT for high-risk neuroblastoma: Results of SMC NB-2009 study - Ji Won Lee
- Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with 131I-metaiodobenzylguanidine - Kelly Huibregtse
- Central nervous system relapses in patients with high-risk neuroblastoma: the SIOPEN experience - Pablo Berlanga
- Autologous T cells expressing a GD2 specific chimeric antigen receptor with CD28 and OX40 costimulatory endodomains for children with neuroblastoma - Andras Heczey
- Killer-cell Ig-like receptor (KIR) haplotypes and Fcγ-receptor polymorphisms correlate with antibody-dependent cell-mediated cytotoxicity levels and survival of high-risk relapsed/refractory neuroblastoma patients treated by long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 (IL-2). - Holger N Lode
- A Phase I Study of Lenalidomide in Combination with ch14.18 and isotretinoin in Patients with Refractory/Recurrent Neuroblastoma (RR-NB): New Approaches to Neuroblastoma Therapy (NANT) Consortium Trial - Araz Marachelian
Neuroblastoma Update - 2
1:30PM - 3:30PM
Thursday, 23rd June
Hall A
Chairs: Sue Cohn & Andy Pearson
Afternoon Tea
3:30PM - 4:00PM
Thursday, 23rd June
Exhibition Area
Keynote 4 – Stephan Grupp
4:00PM - 4:45PM
Thursday, 23rd June
Hall A
Chair: Julie Park
Sponsored by:
ANR Closing Ceremony
4:45PM - 5:15PM
Thursday, 23rd June
Hall A
Chair: Michelle Haber
Conference Dinner
7:00PM - 10:00PM
Thursday, 23rd June
Hall 2